STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: MEDA AB (STO:MEDAA): The New Drug Application (NDA) for a newly formulated higher strength azelastine nasal spray has now been accepted by the Food and Drug Administration (FDA) as complete for substantive review after initial evaluation.
